GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (GREY:OBSEF) » Definitions » FCF Yield %

ObsEva (ObsEva) FCF Yield % : -3,952.39 (As of May. 05, 2024)


View and export this data going back to 2017. Start your Free Trial

What is ObsEva FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, ObsEva's Trailing 12-Month Free Cash Flow is $-23.16 Mil, and Market Cap is $0.16 Mil. Therefore, ObsEva's FCF Yield % for today is -3,952.39%.

The historical rank and industry rank for ObsEva's FCF Yield % or its related term are showing as below:

OBSEF' s FCF Yield % Range Over the Past 10 Years
Min: -100700   Med: 0   Max: 0
Current: -3952.39


OBSEF's FCF Yield % is not ranked
in the Biotechnology industry.
Industry Median: -14.39 vs OBSEF: -3952.39

ObsEva's FCF Margin % for the quarter that ended in Dec. 2022 was 40.34%.


ObsEva FCF Yield % Historical Data

The historical data trend for ObsEva's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ObsEva FCF Yield % Chart

ObsEva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
FCF Yield %
Get a 7-Day Free Trial Premium Member Only -11.66 -56.16 -59.12 -31.70 -148.21

ObsEva Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.91 -48.28 -31.55 -137.90 202.87

Competitive Comparison of ObsEva's FCF Yield %

For the Biotechnology subindustry, ObsEva's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ObsEva's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ObsEva's FCF Yield % distribution charts can be found below:

* The bar in red indicates where ObsEva's FCF Yield % falls into.



ObsEva FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

ObsEva's FCF Yield % for the fiscal year that ended in Dec. 2022 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-23.146 / 15.617515
=-148.21%

ObsEva's annualized FCF Yield % for the quarter that ended in Dec. 2022 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=7.921 * 4 / 15.617515
=202.87%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ObsEva FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


ObsEva FCF Yield % Related Terms

Thank you for viewing the detailed overview of ObsEva's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


ObsEva (ObsEva) Business Description

Traded in Other Exchanges
N/A
Address
Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of innovative women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.
Executives
William Michael Brown officer: Chief Financial Officer 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Anne Vanlent director C/O BARRIER THERAPEUTICS, INC., 600 COLLEGE ROAD EAST, SUITE 3200, PRINCETON NJ 08540
Edward T Mathers director C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Brian O'callaghan director, officer: Chief Executive Officer 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Ernest Loumaye director C/O OBSEVA SA, CHEMIN DES AULX, 12, OLAN-LES-OUATES, GENEVA V8 1228
Catarina Edfjall director C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 0000000000
Annette Clancy director C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 1228
Stephanie Clare Brown director C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 1228

ObsEva (ObsEva) Headlines

From GuruFocus

ObsEva Announces Corporate Updates

By GuruFocusNews GuruFocusNews 07-06-2022

Medicxi Ventures Management (Jersey) Ltd Buys 3, Sells 2 in 4th Quarter

By GuruFocus Research GuruFocus Editor 02-01-2023